Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular's stock jumps on new data for depression drug
08:16am, Tuesday, 28'th Mar 2023
Shares of Intra-Cellular Therapies Inc. ITCI, +2.46% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive disorder met the primary en
Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines
01:39pm, Thursday, 02'nd Mar 2023 Zacks Investment Research
Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.
Analyst Ratings for Intra-Cellular Therapies
12:00pm, Thursday, 02'nd Mar 2023 Benzinga
Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines
09:47am, Thursday, 02'nd Mar 2023
Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
01:45pm, Wednesday, 01'st Mar 2023 Zacks Investment Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
12:30pm, Wednesday, 01'st Mar 2023 GlobeNewswire Inc.
Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
09:47am, Wednesday, 01'st Mar 2023
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
03:00pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Seer, Inc. (SEER) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Intra-Cellular Therapies (ITCI) Report Negative Earnings Next Week? What You Should Know
03:00pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates
10:25pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
01:00pm, Tuesday, 14'th Feb 2023 GlobeNewswire Inc.
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central n
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
08:00am, Tuesday, 14'th Feb 2023
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
01:00pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
08:00am, Wednesday, 08'th Feb 2023
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
01:00pm, Tuesday, 03'rd Jan 2023 GlobeNewswire Inc.
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne
